Vera Therapeutics to Host Business Update Call
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will host a business update call on March 24, 2022, at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will host a business update call on March 24, 2022, at 8:00 a.m. ET. The company is focused on developing transformative treatments for serious immunological diseases. Investors can participate via a toll-free number or an international line, and a webcast will be available 15 minutes prior to the call. Vera's lead candidate, atacicept, targets autoimmune diseases such as IgA nephropathy and lupus nephritis. For details, visit www.veratx.com.
Details
News Market Reaction – VERA
The recorded move for VERA in the trading session of this news was -1.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on March 24, 2022.
| Title: | Vera Therapeutics Business Update Call |
| Date: | Thursday, March 24, 2022 |
| Time: | 8:00 a.m. ET |
| Conference Call Details: | Toll-Free: 1-877-423-9813 International: 1-201-689-8573 Conference ID: 13727899 |
| Webcast: | Webcast Link- Click Here |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on Vera Therapeutics’ website.
About Vera Therapeutics
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Kathy Vincent
Greig Communications, Inc.
kathy@greigcommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.